Rigel Pharma Live Stock Price Today, Share Analysis and Chart

Name: Rigel Pharmaceuticals: Is Infosys Ltd. worth buying?
Item: Rigel Pharmaceuticals
Rating: 2.235416625
Author: Trendlyne DVM scores

Risky Value

about

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsi...

27.53 0.03 (0.11%)

47.30% Fall from 52W High

186.5K

XNAS Volume

XNAS 02 Apr, 2026 5:30 PM (EDT)

Low Financial Strength

33.3 / 100

Affordable Valuation

72.2 / 100

Technically Neutral

40.0 / 100

Risky Value These stocks have weak financials and average momentum. They may be affordable, but investors should exercise caution View Similar Embed DVM

1Yr Price target upside is 86%

5 analysts

Rigel Pharma Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Rigel Pharma Live Stock Price Today, Share Analysis and Chart

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsi...

47.30% Fall from 52W High

SWOT Analysis

Rigel Pharma Live Price Chart